A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 276
- Registration Number
- NCT04245839
- Locations
- 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇺🇸UCLA Medical Centre-Santa Monica, Santa Monica, California, United States
Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT04231435
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT04211558
- Locations
- 🇨🇳
Capital Medical University - Beijing Anzhen Hospital, Beijing, China
Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT04211545
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 13
- Registration Number
- NCT04196491
- Locations
- 🇺🇸
Local Institution - 117, Hackensack, New Jersey, United States
🇺🇸Local Institution - 108, Atlanta, Georgia, United States
🇺🇸Local Institution - 110, Los Angeles, California, United States
Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT04149678
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 99
- Registration Number
- NCT04143724
- Locations
- 🇱🇧
Local Institution - 700, Beirut, Lebanon
🇹🇭Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭Siriraj Hospital Mahidol University, Bangkok, Thailand
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 250
- Registration Number
- NCT04140305
- Locations
- 🇺🇸
Local Institution - 143, Saint Louis, Missouri, United States
🇺🇸Advanced Neurology Specialists, Great Falls, Montana, United States
🇺🇸Local Institution - 149, Teaneck, New Jersey, United States
Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort
- Conditions
- Hepatic Insufficiency
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT04097704
- Locations
- 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Japanese Pharmacokinetic Bridging Study for CC-93538
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT04096105
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States